Cellusion Inc.

Cellusion Inc. is a Japanese biotechnology company founded in 2015, focusing on regenerative medicine through the use of induced pluripotent stem (iPS) cells.

The company develops therapies for corneal blindness, particularly targeting conditions like bullous keratopathy. Headquartered in Tokyo, Cellusion operates as a privately held firm with a dedicated team of 11-50 employees. The company has made significant strides in its field, including the development of its main product, CLS001, a corneal endothelial cell substitute currently in Phase 1 clinical trials. Cellusion also has several other products in various stages of development, aimed at treating corneal and retinal diseases, as well as metabolic disorders. The company collaborates with notable partners, including Celregen and Minaris Regenerative Medicine, to expand its reach and enhance its offerings in regenerative medicine. Cellusion is committed to addressing unmet needs in corneal transplantation and aims to improve healthcare outcomes globally.